Drug Description for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets

Product Name:

Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets

Drug Class and Categories:

• Drug Class: Antiretroviral, Integrase Strand Transfer Inhibitor (INSTI), Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

• Categories: HIV Treatment, Antiretroviral Therapy (ART)

Active Ingredients:

• Dolutegravir

• Emtricitabine

• Tenofovir Alafenamide

Other Names:

• Dovato (a similar combination excluding Tenofovir Alafenamide)

• Descovy (Emtricitabine and Tenofovir Alafenamide combination)

• Tivicay (Dolutegravir)

Mode of Action:

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the HIV integrase enzyme, preventing the viral DNA from integrating into the host cell DNA, thereby inhibiting HIV replication. Emtricitabine and Tenofovir Alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme, crucial for HIV to replicate. Together, they effectively reduce the viral load in the body and manage HIV infection.

How to Use:

• Take one tablet by mouth once daily, with or without food.

• Swallow the tablet whole with a glass of water.

Recommended Dosage:

• Adults and Adolescents (weighing at least 35 kg): One tablet (comprising Dolutegravir 50mg, Emtricitabine 200mg, and Tenofovir Alafenamide 25mg) once daily.

Directions:

1. Starting the Medication:

   • Follow the prescription provided by your healthcare provider.

2. Daily Use:

   • Take the medication at the same time each day to maintain consistent drug levels in your body.

3. Missed Dose:

   • If you miss a dose, take it as soon as you remember. If it is near the time for the next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose.

Cautions:

• Not recommended for use in individuals with severe liver or kidney problems.

• Inform your healthcare provider about any other medications you are taking to avoid potential interactions.

• Regularly monitor kidney function and liver function during treatment.

• Not suitable for individuals with known hypersensitivity to any of the components of the drug.

Guidelines:

• Use Dolutegravir, Emtricitabine, and Tenofovir Alafenamide as part of a complete HIV treatment regimen.

• Do not discontinue use without consulting your healthcare provider.

• Attend all scheduled appointments and lab tests to monitor your health.

• Store the medication at room temperature, away from moisture and heat.

Frequently Asked Questions (FAQs):

Q: What is Dolutegravir, Emtricitabine, and Tenofovir Alafenamide used for?

A: This combination is used to treat HIV-1 infection in adults and adolescents. It helps manage HIV infection by reducing the viral load in the body.

Q: Can Dolutegravir, Emtricitabine, and Tenofovir Alafenamide be taken with other medications?

A: Some medications may interact with this combination, reducing its effectiveness or increasing the risk of side effects. Inform your healthcare provider about all medications and supplements you are taking.

Q: Are there any side effects of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide?

A: Common side effects include headache, nausea, diarrhea, and fatigue. Serious side effects may include kidney problems, liver problems, and lactic acidosis. Contact your healthcare provider if you experience severe symptoms.

Q: How effective is Dolutegravir, Emtricitabine, and Tenofovir Alafenamide in treating HIV?

A: When taken as prescribed, this combination is highly effective in reducing viral load and managing HIV infection.

Q: Can Dolutegravir, Emtricitabine, and Tenofovir Alafenamide be used during pregnancy?

A: If you are pregnant or planning to become pregnant, consult your healthcare provider. The safety of this combination during pregnancy is not well established.

Q: How should I store Dolutegravir, Emtricitabine, and Tenofovir Alafenamide? A: Store the medication at room temperature, away from moisture and heat. Keep it in its original packaging until use.

Q: What should I do if I miss a dose of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide?

A: If you miss a dose, take it as soon as you remember. If it is near the time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose.

Q: Can Dolutegravir, Emtricitabine, and Tenofovir Alafenamide cause kidney problems?

A: Yes, this combination can cause kidney problems. Regular monitoring of kidney function is recommended during treatment.

Q: What is the difference between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate?

A: Tenofovir Alafenamide (TAF) is a newer form of Tenofovir that is more efficient at delivering the active drug to the cells where HIV replicates, allowing for lower doses and potentially fewer side effects compared to Tenofovir Disoproxil Fumarate (TDF).

Q: How long do I need to take Dolutegravir, Emtricitabine, and Tenofovir Alafenamide?

A: HIV treatment is typically lifelong. It is crucial to take the medication as prescribed and attend regular check-ups with your healthcare provider.

By following these guidelines and using Dolutegravir, Emtricitabine, and Tenofovir Alafenamide as prescribed, you can effectively manage HIV infection. Always consult your healthcare provider for personalized advice and information.